Oliver George Hayes
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Oliver George Hayes has a total of 57 co-authors. Here are the top co-authors by number of shared publications:
- Chad Alexander Mirkin
Northwestern University
6 shared publications - Benjamin E. Partridge
Department of Chemistry, University of Rochester, Rochester, NY 14627-0216, USA
2 shared publications E. Filipiak
Division of Biomolecular and Cellular Medicine, Department of Laboratory Medicine, Karolinska Institutet, Huddinge, 14152, Stockholm, Sweden
2 shared publications- Janet R. McMillan
Core R&D The Dow Chemical Company Midland Michigan USA
2 shared publications M. Ojansivu
Division of Biomolecular and Cellular Medicine, Department of Laboratory Medicine, Karolinska Institutet, Huddinge, 14152, Stockholm, Sweden
2 shared publications- Peter H. Winegar
Joint BioEnergy Institute, Lawrence Berkeley National Laboratory
2 shared publications
Latest Publications
- Open Access
Customizable bead-based platform for EV surface protein immunocapture and detection in plasma
Extracellular vesicles (EVs) are increasingly recognized as valuable biomarkers for liquid biopsy because they carry molecular signatures that reflect their cells of origin. However, EV isolation remains a challenge, and existing EV immunocapture platforms are constrained by nonspecific binding, limited flexibility, and insufficient sensitivity. Here, we present a customizable bead-based platform for the isolation and detection of specific EV populations directly from plasma. The platform combines bead-immobilized capture antibodies with fluorescent detection antibodies, enabling sensitive and multiplexed EV profiling. Optimization of bead conjugation chemistry improved antibody immobilization and reduced nonspecific background signals, enhancing assay specificity and performance. Using breast cancer-derived EVs expressing fluorescent protein, we demonstrate the detection of tumor-derived EVs in plasma at concentrations as low as 1 × 10 9 EVs/ml. Furthermore, the assay distinguished HER2- and TROP2-high from low EV populations, demonstrating its ability to detect clinically relevant differences in biomarker expression. The workflow is compatible with direct EV analysis in the unprocessed plasma samples, thereby reducing sample preparation requirements and assay complexity. These findings establish a sensitive, flexible, and scalable platform for EV biomarker analysis. The approach overcomes several limitations of current commercial bead-based technologies and may facilitate the development of customizable multiplexed EV-based assays for cancer detection, patient stratification, and disease monitoring.
Open AccessCustomizable bead-based platform for EV surface protein immunocapture and detection in plasma
Extracellular vesicles (EVs) are increasingly recognized as valuable biomarkers for liquid biopsy because they carry molecular signatures that reflect their cells of origin. However, EV isolation remains a challenge, and existing EV immunocapture platforms are constrained by nonspecific binding, limited flexibility, and insufficient sensitivity. Here, we present a customizable bead-based platform for the isolation and detection of specific EV populations directly from plasma. The platform combines bead-immobilized capture antibodies with fluorescent detection antibodies, enabling sensitive and multiplexed EV profiling. Optimization of bead conjugation chemistry improved antibody immobilization and reduced nonspecific background signals, enhancing assay specificity and performance. Using breast cancer-derived EVs expressing fluorescent protein, we demonstrate the detection of tumor-derived EVs in plasma at concentrations as low as 1 × 10 9 EVs/ml. Furthermore, the assay distinguished HER2- and TROP2-high from low EV populations, demonstrating its ability to detect clinically relevant differences in biomarker expression. The workflow is compatible with direct EV analysis in the unprocessed plasma samples, thereby reducing sample preparation requirements and assay complexity. These findings establish a sensitive, flexible, and scalable platform for EV biomarker analysis. The approach overcomes several limitations of current commercial bead-based technologies and may facilitate the development of customizable multiplexed EV-based assays for cancer detection, patient stratification, and disease monitoring.
- Open Access
Enhancing the efficacy of siRNA Antibody Oligonucleotide Conjugates (AOCs) through chemical design
Antibody-oligonucleotide conjugates (AOCs) offer a promising solution to delivery challenges of therapeutic oligonucleotides. However, the relationship between their complex chemical architectures and biological activity remains poorly understood, limiting the development of important structure-function relationships. For siRNA-containing AOCs, increasing the siRNA-to-antibody ratio beyond one (drug-to-antibody ratio, DAR>1) reduces potency, attributed to altered pharmacokinetics arising from increased negative charge density. Here, we investigated whether simple chemical modifications could improve AOC efficacy and mitigate limitations associated with higher DAR. Introduction of a single C16 lipid modification to the siRNA significantly enhanced target gene silencing compared to the unmodified AOC. Extending this modification to a DAR2 architecture, in which two siRNAs are conjugated per antibody, restored the loss of activity associated with increasing DAR from 1 to 2. Notably, at an equivalent siRNA dose (1 mg/kg), the DAR2-C16 AOC requires half the amount of antibody while achieving knockdown comparable to the DAR1-C16 AOC. We also developed a charge-balancing ionizable linker (CBIL) designed to partially compensate for the negative charge of siRNA. Incorporation of the CBIL enhanced target gene silencing in heart and skeletal muscle without a corresponding increase in hepatic activity, resulting in a shift toward greater extrahepatic activity relative to liver. Together, these findings demonstrate that chemical modification of both the siRNA payload and antibody-siRNA linker can be used to tune AOC potency and tissue activity, while enabling higher payload loading without compromising efficacy. These results establish chemical design as an important strategy for expanding the architecture and therapeutic potential of AOCs. TOC Graphic:
Open AccessEnhancing the efficacy of siRNA Antibody Oligonucleotide Conjugates (AOCs) through chemical design
Antibody-oligonucleotide conjugates (AOCs) offer a promising solution to delivery challenges of therapeutic oligonucleotides. However, the relationship between their complex chemical architectures and biological activity remains poorly understood, limiting the development of important structure-function relationships. For siRNA-containing AOCs, increasing the siRNA-to-antibody ratio beyond one (drug-to-antibody ratio, DAR>1) reduces potency, attributed to altered pharmacokinetics arising from increased negative charge density. Here, we investigated whether simple chemical modifications could improve AOC efficacy and mitigate limitations associated with higher DAR. Introduction of a single C16 lipid modification to the siRNA significantly enhanced target gene silencing compared to the unmodified AOC. Extending this modification to a DAR2 architecture, in which two siRNAs are conjugated per antibody, restored the loss of activity associated with increasing DAR from 1 to 2. Notably, at an equivalent siRNA dose (1 mg/kg), the DAR2-C16 AOC requires half the amount of antibody while achieving knockdown comparable to the DAR1-C16 AOC. We also developed a charge-balancing ionizable linker (CBIL) designed to partially compensate for the negative charge of siRNA. Incorporation of the CBIL enhanced target gene silencing in heart and skeletal muscle without a corresponding increase in hepatic activity, resulting in a shift toward greater extrahepatic activity relative to liver. Together, these findings demonstrate that chemical modification of both the siRNA payload and antibody-siRNA linker can be used to tune AOC potency and tissue activity, while enabling higher payload loading without compromising efficacy. These results establish chemical design as an important strategy for expanding the architecture and therapeutic potential of AOCs. TOC Graphic:
- Open Access
- 27 May 2026
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 37 (6) , 1121-1128
Investigating the In Vivo Performance of Tannic Acid-Modified siRNA in the Heart and Liver
Effective extrahepatic activity of therapeutic oligonucleotides remains an unresolved and significant problem in the development of new genetic medicines. Targeted delivery to the heart is of particular interest due to the unmet need to treat an increasing health burden of cardiovascular diseases and the identification of potential genetic therapeutic targets. Drawing inspiration from literature, we investigate the potential of tannic acid (TA) modifications to improve the activity of a model siRNA sequence in the heart. We developed the synthesis of a series of conjugates containing 1–3 (TA) units to study how molecularly defined numbers of TA ligands influence activity. While we observe significant knockdown of the siRNA target gene in the liver, we did not in the heart, suggesting that although TA ligands confer improved function of siRNA in the liver, extrahepatic activity was not enhanced. In addition, hetero-bifunctional siRNA conjugates containing both TA and albumin binding motifs were designed and their synergistic effects explored. Similarly, in vivo data suggests that TA ligands do not increase cardiac activity of siRNA in this context; however, we can conclude that both C16 and AlbuTag ligands do significantly improve siRNA activity in the heart. We believe this work provides important bioconjugation insight for polyphenolic molecules, like tannic acid, as well as the synthesis of hetero-bifunctional siRNA conjugates generally. Moreover, our findings will inform the design of novel targeting ligands and nanomaterials, especially for molecules that may possess emergent properties when present in high multiplicity compared to their monomeric forms.
- 27 May 2026
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 37 (6) , 1121-1128
Open AccessInvestigating the In Vivo Performance of Tannic Acid-Modified siRNA in the Heart and Liver
Effective extrahepatic activity of therapeutic oligonucleotides remains an unresolved and significant problem in the development of new genetic medicines. Targeted delivery to the heart is of particular interest due to the unmet need to treat an increasing health burden of cardiovascular diseases and the identification of potential genetic therapeutic targets. Drawing inspiration from literature, we investigate the potential of tannic acid (TA) modifications to improve the activity of a model siRNA sequence in the heart. We developed the synthesis of a series of conjugates containing 1–3 (TA) units to study how molecularly defined numbers of TA ligands influence activity. While we observe significant knockdown of the siRNA target gene in the liver, we did not in the heart, suggesting that although TA ligands confer improved function of siRNA in the liver, extrahepatic activity was not enhanced. In addition, hetero-bifunctional siRNA conjugates containing both TA and albumin binding motifs were designed and their synergistic effects explored. Similarly, in vivo data suggests that TA ligands do not increase cardiac activity of siRNA in this context; however, we can conclude that both C16 and AlbuTag ligands do significantly improve siRNA activity in the heart. We believe this work provides important bioconjugation insight for polyphenolic molecules, like tannic acid, as well as the synthesis of hetero-bifunctional siRNA conjugates generally. Moreover, our findings will inform the design of novel targeting ligands and nanomaterials, especially for molecules that may possess emergent properties when present in high multiplicity compared to their monomeric forms.
- Open Access
- 27 December 2025
- Published by Elsevier in Extracellular Vesicle
- Vol. 7
Injected extracellular vesicles and other nanoparticles hitchhike on erythrocytes and platelets from circulation towards organ clearance
- 27 December 2025
- Published by Elsevier in Extracellular Vesicle
- Vol. 7
Open AccessInjected extracellular vesicles and other nanoparticles hitchhike on erythrocytes and platelets from circulation towards organ clearance
- Open Access
- 26 April 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (17) , eado8020
Reversible strain-promoted DNA polymerization
Molecular strain can be introduced to influence the outcome of chemical reactions. Once a thermodynamic product is formed, however, reversing the course of a strain-promoted reaction is challenging. Here, a reversible, strain-promoted polymerization in cyclic DNA is reported. The use of nonhybridizing, single-stranded spacers as short as a single nucleotide in length can promote DNA cyclization. Molecular strain is generated by duplexing the spacers, leading to ring opening and subsequent polymerization. Then, removal of the strain-generating duplexers triggers depolymerization and cyclic dimer recovery via enthalpy-driven cyclization and entropy-mediated ring contraction. This reversibility is retained even when a protein is conjugated to the DNA strands, and the architecture of the protein assemblies can be modulated between bivalent and polyvalent states. This work underscores the utility of using DNA not only as a programmable ligand for assembly but also as a route to access restorable bonds, thus providing a molecular basis for DNA-based materials with shape-memory, self-healing, and stimuli-responsive properties.
- 26 April 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (17) , eado8020
Open AccessReversible strain-promoted DNA polymerization
Molecular strain can be introduced to influence the outcome of chemical reactions. Once a thermodynamic product is formed, however, reversing the course of a strain-promoted reaction is challenging. Here, a reversible, strain-promoted polymerization in cyclic DNA is reported. The use of nonhybridizing, single-stranded spacers as short as a single nucleotide in length can promote DNA cyclization. Molecular strain is generated by duplexing the spacers, leading to ring opening and subsequent polymerization. Then, removal of the strain-generating duplexers triggers depolymerization and cyclic dimer recovery via enthalpy-driven cyclization and entropy-mediated ring contraction. This reversibility is retained even when a protein is conjugated to the DNA strands, and the architecture of the protein assemblies can be modulated between bivalent and polyvalent states. This work underscores the utility of using DNA not only as a programmable ligand for assembly but also as a route to access restorable bonds, thus providing a molecular basis for DNA-based materials with shape-memory, self-healing, and stimuli-responsive properties.
- 30 September 2021
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 118 (40)
Encoding hierarchical assembly pathways of proteins with DNA
Significance: Structural sophistication in nature would not be possible without hierarchical assembly: the concept that an initial building block (e.g., polypeptide) contains all necessary structural and chemical information to determine its assembly along a multistep pathway to generate a complex architecture (e.g., viral capsid). Translating this concept to synthetic systems is an outstanding challenge. Here, we use DNA—the blueprint of life—to direct the hierarchical assembly of proteins. Through DNA design, we can change the directionality of protein assembly and pathway by which protein–DNA conjugates will assemble as well as realize distinct structures by directing assembly along different pathways. These findings will facilitate the assembly of protein–DNA materials with structural complexity more closely approaching that observed in nature.
- 30 September 2021
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 118 (40)
Encoding hierarchical assembly pathways of proteins with DNA
Significance: Structural sophistication in nature would not be possible without hierarchical assembly: the concept that an initial building block (e.g., polypeptide) contains all necessary structural and chemical information to determine its assembly along a multistep pathway to generate a complex architecture (e.g., viral capsid). Translating this concept to synthetic systems is an outstanding challenge. Here, we use DNA—the blueprint of life—to direct the hierarchical assembly of proteins. Through DNA design, we can change the directionality of protein assembly and pathway by which protein–DNA conjugates will assemble as well as realize distinct structures by directing assembly along different pathways. These findings will facilitate the assembly of protein–DNA materials with structural complexity more closely approaching that observed in nature.
- 1 May 2020
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 142 (19) , 8596-8601
Controlling the DNA Hybridization Chain Reaction
A novel method for controlling the oligomerization of metastable DNA hairpins using the hybridization chain reaction (HCR) is reported. Control was achieved through the introduction of a base-pair mismatch in the duplex of the hairpins. The mismatch modification allows one to kinetically differentiate initiation versus propagation events, leading to DNA oligomers up to 10 monomers long and improving dispersities from 2.5 to 1.3–1.6. Importantly, even after two consecutive chain extensions, dispersity remained unaffected, showing that well-defined block co-oligomers can be achieved. As a proof-of-concept, this technique was then applied to hairpin monomers functionalized with a mutant green fluorescent protein to prepare protein oligomers. Taken together, this work introduces an effective method for controlling living macromolecular HCR oligomerization in a manner analogous to the controlled polymerization of small molecules.
- 1 May 2020
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 142 (19) , 8596-8601
Controlling the DNA Hybridization Chain Reaction
A novel method for controlling the oligomerization of metastable DNA hairpins using the hybridization chain reaction (HCR) is reported. Control was achieved through the introduction of a base-pair mismatch in the duplex of the hairpins. The mismatch modification allows one to kinetically differentiate initiation versus propagation events, leading to DNA oligomers up to 10 monomers long and improving dispersities from 2.5 to 1.3–1.6. Importantly, even after two consecutive chain extensions, dispersity remained unaffected, showing that well-defined block co-oligomers can be achieved. As a proof-of-concept, this technique was then applied to hairpin monomers functionalized with a mutant green fluorescent protein to prepare protein oligomers. Taken together, this work introduces an effective method for controlling living macromolecular HCR oligomerization in a manner analogous to the controlled polymerization of small molecules.
- 14 June 2019
- Published by American Chemical Society (ACS) in Accounts of Chemical Research
- Vol. 52 (7) , 1939-1948
Protein Materials Engineering with DNA
Proteins are a class of nanoscale building block with remarkable chemical complexity and sophistication: their diverse functions, shapes, and symmetry as well as atomically monodisperse structures far surpass the range of conventional nanoparticles that can be accessed synthetically. The chemical topologies of proteins that drive their assembly into materials are central to their functions in nature. However, despite the importance of protein materials in biology, efforts to harness these building blocks synthetically to engineer new materials have been impeded by the chemical complexity of protein surfaces, making it difficult to reliably design protein building blocks that can be robustly transformed into targeted materials. Here we describe our work aimed at exploiting a simple but important concept: if one could exchange complex protein–protein interactions with well-defined and programmable DNA–DNA interactions, one could control the assembly of proteins into structurally well-defined oligomeric and polymeric materials and three-dimensional crystals. As a class of nanoscale building block, proteins with surface DNA modifications have a vast design space that exceeds what is practically and conceptually possible with their inorganic counterparts: the sequences of the DNA and protein and the chemical nature and position of DNA attachment all play roles in dictating the assembly behavior of protein–DNA conjugates. We summarize how each of these design parameters can influence structural outcome, beginning with proteins with a single surface DNA modification, where energy barriers between protein monomers can be tuned through the sequence and secondary structure of the oligonucleotide. We then explore challenges and progress in designing directional interactions and valency on protein surfaces. The directional binding properties of protein–DNA conjugates are ultimately imposed by the amino acid sequence of the protein, which defines the spatial distribution of DNA modification sites on the protein. Through careful design and mutagenesis, bivalent building blocks that bind directionally to form one-dimensional assemblies can be realized. Finally, we discuss the assembly of proteins densely modified with DNA into crystalline superlattices. At first glance, these protein building blocks display crystallization behavior remarkably similar to that of their DNA-functionalized inorganic nanoparticle counterparts, which allows design principles elucidated for DNA-guided nanoparticle crystallization to be used as predictive tools in determining structural outcomes in protein systems. Proteins additionally offer design handles that nanoparticles do not: unlike nanoparticles, the number and spatial distribution of DNA can be controlled through the protein sequence and DNA modification chemistry. Changing the spatial distributions of DNA can drive otherwise identical proteins down distinct crystallization pathways and yield building blocks with exotic distributions of DNA that crystallize into structures that are not yet attainable using isotropically functionalized particles. We highlight challenges in accessing other classes of architectures and establishing general design rules for DNA-mediated protein assembly. Harnessing surface DNA modifications to build protein materials creates many opportunities to realize new architectures and answer fundamental questions about DNA-modified nanostructures in both materials and biological contexts. Proteins with surface DNA modifications are a powerful class of nanomaterial building blocks for which the DNA and protein sequences and the nature of their conjugation dictate the material structure.
- 14 June 2019
- Published by American Chemical Society (ACS) in Accounts of Chemical Research
- Vol. 52 (7) , 1939-1948
Protein Materials Engineering with DNA
Proteins are a class of nanoscale building block with remarkable chemical complexity and sophistication: their diverse functions, shapes, and symmetry as well as atomically monodisperse structures far surpass the range of conventional nanoparticles that can be accessed synthetically. The chemical topologies of proteins that drive their assembly into materials are central to their functions in nature. However, despite the importance of protein materials in biology, efforts to harness these building blocks synthetically to engineer new materials have been impeded by the chemical complexity of protein surfaces, making it difficult to reliably design protein building blocks that can be robustly transformed into targeted materials. Here we describe our work aimed at exploiting a simple but important concept: if one could exchange complex protein–protein interactions with well-defined and programmable DNA–DNA interactions, one could control the assembly of proteins into structurally well-defined oligomeric and polymeric materials and three-dimensional crystals. As a class of nanoscale building block, proteins with surface DNA modifications have a vast design space that exceeds what is practically and conceptually possible with their inorganic counterparts: the sequences of the DNA and protein and the chemical nature and position of DNA attachment all play roles in dictating the assembly behavior of protein–DNA conjugates. We summarize how each of these design parameters can influence structural outcome, beginning with proteins with a single surface DNA modification, where energy barriers between protein monomers can be tuned through the sequence and secondary structure of the oligonucleotide. We then explore challenges and progress in designing directional interactions and valency on protein surfaces. The directional binding properties of protein–DNA conjugates are ultimately imposed by the amino acid sequence of the protein, which defines the spatial distribution of DNA modification sites on the protein. Through careful design and mutagenesis, bivalent building blocks that bind directionally to form one-dimensional assemblies can be realized. Finally, we discuss the assembly of proteins densely modified with DNA into crystalline superlattices. At first glance, these protein building blocks display crystallization behavior remarkably similar to that of their DNA-functionalized inorganic nanoparticle counterparts, which allows design principles elucidated for DNA-guided nanoparticle crystallization to be used as predictive tools in determining structural outcomes in protein systems. Proteins additionally offer design handles that nanoparticles do not: unlike nanoparticles, the number and spatial distribution of DNA can be controlled through the protein sequence and DNA modification chemistry. Changing the spatial distributions of DNA can drive otherwise identical proteins down distinct crystallization pathways and yield building blocks with exotic distributions of DNA that crystallize into structures that are not yet attainable using isotropically functionalized particles. We highlight challenges in accessing other classes of architectures and establishing general design rules for DNA-mediated protein assembly. Harnessing surface DNA modifications to build protein materials creates many opportunities to realize new architectures and answer fundamental questions about DNA-modified nanostructures in both materials and biological contexts. Proteins with surface DNA modifications are a powerful class of nanomaterial building blocks for which the DNA and protein sequences and the nature of their conjugation dictate the material structure.
- 8 November 2018
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 140 (46) , 15950-15956
Programming Protein Polymerization with DNA
A strategy that utilizes DNA for controlling the association pathway of proteins is described. This strategy uses sequence-specific DNA interactions to program energy barriers for polymerization, allowing for either step-growth or chain-growth pathways to be accessed. Two sets of mutant green fluorescent protein (mGFP)–DNA monomers with single DNA modifications have been synthesized and characterized. Depending on the deliberately controlled sequence and conformation of the appended DNA, these monomers can be polymerized through either a step-growth or chain-growth pathway. Cryo-electron microscopy with Volta phase plate technology enables the visualization of the distribution of the oligomer and polymer products, and even the small mGFP–DNA monomers. Whereas cyclic and linear polymer distributions were observed for the step-growth DNA design, in the case of the chain-growth system linear chains exclusively were observed, and a dependence of the chain length on the concentration of the initiator strand was noted. Importantly, the chain-growth system possesses a living character whereby chains can be extended with the addition of fresh monomer. This work represents an important and early example of mechanistic control over protein assembly, thereby establishing a robust methodology for synthesizing oligomeric and polymeric protein-based materials with exceptional control over architecture.
- 8 November 2018
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 140 (46) , 15950-15956
Programming Protein Polymerization with DNA
A strategy that utilizes DNA for controlling the association pathway of proteins is described. This strategy uses sequence-specific DNA interactions to program energy barriers for polymerization, allowing for either step-growth or chain-growth pathways to be accessed. Two sets of mutant green fluorescent protein (mGFP)–DNA monomers with single DNA modifications have been synthesized and characterized. Depending on the deliberately controlled sequence and conformation of the appended DNA, these monomers can be polymerized through either a step-growth or chain-growth pathway. Cryo-electron microscopy with Volta phase plate technology enables the visualization of the distribution of the oligomer and polymer products, and even the small mGFP–DNA monomers. Whereas cyclic and linear polymer distributions were observed for the step-growth DNA design, in the case of the chain-growth system linear chains exclusively were observed, and a dependence of the chain length on the concentration of the initiator strand was noted. Importantly, the chain-growth system possesses a living character whereby chains can be extended with the addition of fresh monomer. This work represents an important and early example of mechanistic control over protein assembly, thereby establishing a robust methodology for synthesizing oligomeric and polymeric protein-based materials with exceptional control over architecture.
- 10 July 2018
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 140 (29) , 9269-9274
DNA-Encoded Protein Janus Nanoparticles
Asymmetric functionality and directional interactions, which are characteristic of noncentrosymmetric particles, such as Janus particles, present an opportunity to encode particles with properties, but also a great synthetic challenge. Here, we exploit the chemical anisotropy of proteins, and the versatile chemistry of DNA to synthesize a protein-based Janus nanoparticle comprised of two proteins encoded with sequence-specific nucleic acid domains, tethered together by an interprotein “DNA bond”. We use these novel nanoparticles to realize a new class of three-dimensional superlattice, only possible when two sides of the particle are modified with orthogonal oligonucleotide sequences. The low symmetry, intrinsic to Janus particles, enables the realization of unprecedented multicomponent nanoparticle superlattices with unique, hexagonal layered architectures. In addition, the interprotein “DNA bond” can be modulated to selectively expand the lattice in a single direction. The results presented herein not only emphasize the power of rationally designing nanoscale building blocks to create highly engineered colloidal crystals, but also establish a precedent for applications of multidomain DNA-encoded nanoparticles, especially in the field of colloidal crystallization.
- 10 July 2018
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 140 (29) , 9269-9274
DNA-Encoded Protein Janus Nanoparticles
Asymmetric functionality and directional interactions, which are characteristic of noncentrosymmetric particles, such as Janus particles, present an opportunity to encode particles with properties, but also a great synthetic challenge. Here, we exploit the chemical anisotropy of proteins, and the versatile chemistry of DNA to synthesize a protein-based Janus nanoparticle comprised of two proteins encoded with sequence-specific nucleic acid domains, tethered together by an interprotein “DNA bond”. We use these novel nanoparticles to realize a new class of three-dimensional superlattice, only possible when two sides of the particle are modified with orthogonal oligonucleotide sequences. The low symmetry, intrinsic to Janus particles, enables the realization of unprecedented multicomponent nanoparticle superlattices with unique, hexagonal layered architectures. In addition, the interprotein “DNA bond” can be modulated to selectively expand the lattice in a single direction. The results presented herein not only emphasize the power of rationally designing nanoscale building blocks to create highly engineered colloidal crystals, but also establish a precedent for applications of multidomain DNA-encoded nanoparticles, especially in the field of colloidal crystallization.